UNOFFICIAL COPY 25 RS BR 936

1	AN ACT relating to undesignated glucagon.
2	Be it enacted by the General Assembly of the Commonwealth of Kentucky:
3	→SECTION 1. A NEW SECTION OF KRS CHAPTER 217 IS CREATED TO
4	READ AS FOLLOWS:
5	As used in Sections 1 to 3 of this Act:
6	(1) "Administer" means to directly apply glucagon;
7	(2) "Authorized entity" means a public, private, or parochial school that has a
8	trained individual present on the premises or officially associated with the entity
9	who is trained as required under Section 2 of this Act to receive and administer
10	undesignated glucagon;
11	(3) "Diabetes medical management plan" means a written, individualized health
12	plan designed to acknowledge and prepare for the health care needs of a studen
13	diagnosed with diabetes that is prepared by the student's treating practitioner or
14	practitioner team;
15	(4) ''Pharmacist'' has the same meaning as in KRS 315.010;
16	(5) "Practitioner" has the same meaning as in KRS 217.015;
17	(6) "Trained individual" means an individual who has successfully completed an
18	approved education training program under KRS 158.838; and
19	(7) "Undesignated glucagon" means glucagon prescribed in the name of an
20	authorized entity or trained individual in accordance with Sections 1 to 3 of this
21	<u>Act.</u>
22	→SECTION 2. A NEW SECTION OF KRS CHAPTER 217 IS CREATED TO
23	READ AS FOLLOWS:
24	(1) A practitioner, acting within the practitioner's scope of practice, may prescribe
25	undesignated glucagon in the name of an authorized entity or trained individua
26	for use in accordance with this section.

 $\begin{array}{c} \text{Page 1 of 3} \\ \text{XXXX} \quad \text{1/2/2025 12:28 PM} \end{array}$ 

(2) A pharmacist may dispense undesignated glucagon for a prescription issued in

27

UNOFFICIAL COPY 25 RS BR 936

1	the name of an authorized entity or trained individual.
2	(3) A trained individual who has successfully completed the training requirements
3	under KRS 158.838 may:
4	(a) Receive a prescription for undesignated glucagon from a practitioner or
5	pharmacist; and
6	(b) Administer undesignated glucagon in an emergency situation when a
7	school nurse or other licensed practitioner is not immediately available and
8	the trained individual believes in good faith that a student is experiencing
9	severe hypoglycemia or other conditions noted in that student's diabetes
10	medical management plan, regardless of whether that student has a
11	prescription for glucagon.
12	(4) An authorized entity that acquires and stocks a supply of undesignated glucagon
13	with a valid prescription shall:
14	(a) Store the undesignated glucagon in accordance with the manufacturer's
15	instructions and with any additional requirements established by the
16	Department for Public Health; and
17	(b) Designate a trained individual to be responsible for the storage,
18	maintenance, and general oversight of the undesignated glucagon acquired
19	by the authorized entity.
20	(5) Any authorized entity or trained individual that acquires and stocks a supply of
21	undesignated glucagon in accordance with this section shall notify an agent of
22	the local emergency medical services and the local emergency communications or
23	dispatch center of the existence, location, and type of glucagon acquired.
24	(6) Any authorized entity or trained individual that administers or provides
25	undesignated glucagon to a student who is experiencing severe hypoglycemia or
26	other conditions noted in that student's diabetes medical management plan shall
27	contact the student's parent, guardian, or emergency contact, and local

UNOFFICIAL COPY 25 RS BR 936

1	emergency medical services as soon as possible.
2	(7) The requirements of subsection (6) of this section shall not apply to an
3	individual who administers or provides undesignated glucagon if that individua
4	is acting as a Good Samaritan under KRS 313.035 and 411.148.
5	→SECTION 3. A NEW SECTION OF KRS CHAPTER 217 IS CREATED TO
6	READ AS FOLLOWS:
7	(1) Any authorized entity or trained individual that, in good faith and without
8	compensation, renders emergency care or treatment by the use of undesignate
9	glucagon under Sections 1 to 3 of this Act shall be immune from civil liability fo
10	any personal injury resulting from the care or treatment, or resulting from an
11	act or failure to act in providing or arranging further medical treatment, if th
12	person acts as an ordinary, reasonably prudent person would have acted unde
13	the same or similar circumstances.
14	(2) The immunity under subsection (1) of this section applies to:
15	(a) A practitioner who prescribes or authorizes the emergency use of
16	undesignated glucagon;
17	(b) A pharmacist who fills a prescription for undesignated glucagon;
18	(c) A trained individual who administers or provides undesignated glucagon;
19	(d) An authorized entity that acquires and stocks undesignated glucagon, o
20	provides undesignated glucagon to a trained individual; and
21	(e) An individual trainer or training entity providing the required training to
22	trained individual.
23	(3) The immunity under subsection (1) of this section shall not apply if the personal
24	injury results from the gross negligence or willful or wanton misconduct of th
25	nerson rendering the care or treatment